NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Novo exercises its option for an equity stake in SYNLAB

Munich, 15 December 2016 - SYNLAB Limited ('SYNLAB' or 'the Group') today announces that Novo A/S ('Novo') has exercised its option to acquire an equity stake in the Group. Following the closing of the transaction which is scheduled to take place on 15 December 2016, Novo will own a stake of more than 10% of the equity of SYNLAB Limited.

With the exercise of its option, Novo emphasises its ongoing commitment to facilitate SYNLAB's expansion and development through significant financial backing for the Group.

- Ends -

Forward-Looking Information is Subject to Risk and Uncertainty

This press release may include certain 'forward-looking' statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words 'believes,' 'expects,' 'may,' 'will,' 'would,' 'should,' 'seeks,' 'pro forma,' 'anticipates,' 'intends,' 'plans,' 'estimates,' or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and Synlab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information: